Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder

Journal of Clinical Psychiatry

Volumn 66, Issue 3, 2005, Pages 353-359

  Koran, Lorrin M ^a,b   Aboujaoude, Elias ^a   Bullock, Kim D ^a   Franz, Bettina ^a   Gamel, Nona ^a   Elliott, Michael ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LORAZEPAM; MORPHINE SULFATE; MU OPIATE RECEPTOR AGONIST; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAPHORESIS; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; MALE; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SCREENING; SEDATION; SEROTONIN RELEASE; SIDE EFFECT; SUBSTERNAL PAIN; WILCOXON SIGNED RANKS TEST;

EID: 16444370008     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v66n0312     Document Type: Article

References (28)

1. Koran LM. Obsessive-Compulsive and Related Disorders in Adults: A Comprehensive Clinical Guide. Cambridge, UK: Cambridge University Press; 1999
2. Pallanti S, Hollander E, Bienstock C, et al. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 2002;5:181-191
3. Warneke L. A possible new treatment approach to obsessive-compulsive disorder [letter]. Can J Psychiatry 1997;42:667-668
4. Shapira NA, Keck PE, Goldsmith TD, et al. Open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder. Depress Anxiety 1997;6:170-173
5. Saxena S, Brody AL, Schwanz JM, et al. Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. Br J Psychiatry 1998;173(suppl 35):26-37
6. Goodman WK, Price H, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, pt 1: development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-1011
7. Goldsmith TD, Shapira NA, Keck PE. Rapid remission of OCD with tramadol hydrochloride [letter]. Am J Psychiatry 1999;156:660-661
8. Shapira NA, Verduin ML, DeGraw JD. Treatment of refractory major depression with tramadol monotherapy [letter]. J Clin Psychiatry 2001;62:205-206
9. Lecrubier Y, Sheehan D, Weiller E, et al. The Mini-International Neuropsychiatric Interview (MINI) a short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry 1997;12:232-241
10. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
11. Osawa H, Saito M, Fujii M. et al. Postcholecystectomy syndrome mimicking angina pectoris detected by the morphine provocation test. Intern Med 1995;34:51-53
12. Ho AM. Previous cholecystectomy and choledochal sphincter spasm after morphine sedation. Can J Anaesth 2000;47:50-52
13. Insel TR, Pickar D. Naloxone administration in obsessive-compulsive disorder: report of two cases. Am J Psychiatry 1983;140:1219-1220
14. Keuler DJ, Altemus M, Michelson D, et al. Behavioral effects of naloxone infusion in obsessive-compulsive disorder. Biol Psychiatry 1996;40:154-156
15. Sandyk R. Naloxone abolishes obsessive-compulsive behavior in Tourette's syndrome. Int J Neurosci 1987;35:93-94
16. Baxter LR, Ackermann RF, Swerdlow NR, et al. Specific brain system mediation of obsessive-compulsive disorder responsive to either medication or behavior therapy. In: Goodman WK, Rudorfer MV, Maser JD, eds. Obsessive-Compulsive Disorder: Contemporary Issues in Treatment. Mahwah, NJ: L. Erlbaum Associates; 2000:573-609
17. Jolas T, Nestler EJ, Aghajanian GK. Chronic morphine increases GABA tone on serotonergic neurons of the dorsal raphe nucleus: association with an up-regulation of the cyclic AMP pathway. Neuroscience 2000;95:433-443
18. Kalyuzhny AE, Wessendorf MW. Relationship of mu- and delta-opioid receptors to GABAergic neurons in the central nervous system, including antinociceptive brainstem circuits. J Comp Neurol 1998;392:528-547
19. de Gandarias JM, Echevarria E, Acebes 1, et al. Effects of fluoxetine administration on mu-opioid receptor immunostaining in the rat forebrain. Brain Res 1999;817:236-240
20. Marek GJ, Aghajanian GK. 5-Hydroxytryptamine-induced excitatory postsynaptic currents in neocortical layer V pyramidal cells: suppression by mu-opiate receptor activation. Neuroscience 1998;86:485-497
21. Rosenberg DR, Macmaster FP, Keshavan MS, et al. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 2000;39:1096-1103
22. Arnold PD, Rosenberg DR, Mundo E, et al. Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology (Berl) 2004;174:530-538
23. McGrath MJ, Campbell KM, Parks CR, et al. Glutamatergic drugs exacerbate symptomatic behavior in a transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder. Brain Res 2000;877:23-30
24. Steiner H, Gerfen CR. Enkephalin regulates acute D2 dopamine receptor antagonist-induced immediate-early gene expression in striatal neurons. Neuroscience 1999;88:795-810
25. Torres G, Horowitz JM. Drugs of abuse and brain gene expression. Psychosom Med 1999;61:630-650
26. Frankel PS, Harlan RE, Garcia MM. Role of the dorsal raphe nucleus in morphine-induced immediate early gene expression in the rat striatum. Brain Res 1999;842:220-223
27. Gutstein HB, Thome JL, Fine JL, et al. Pattern of c-fos mRNA induction in rat brain by acute morphine. Can J Physiol Pharmacol 1998;76:294-303
28. Loguinov AV, Anderson LM, Crosby GJ, et al. Gene expression following acute morphine administration. Physiol Genomics 2001;6:169-181